AbbVie : Risankizumab Phase 3 Results Demonstrate Improvements in Disease Activity across Joint and Skin Symptoms among Psoriatic Arthritis Patients

NORTH CHICAGO - AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, showing that significantly more patients treated with risankizumab achieved the primary endpoint of ACR20 response at week 24 versus placebo.1

In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo (p

(C) 2021 Electronic News Publishing, source ENP Newswire